Title: | Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas : A single-institution retrospective study in Japan |
Authors: | Sakashita, Tomohiro Browse this author →KAKEN DB |
Homma, Akihiro Browse this author →KAKEN DB |
Hatakeyama, Hiromitsu Browse this author →KAKEN DB |
Furusawa, Jun Browse this author |
Kano, Satoshi Browse this author →KAKEN DB |
Mizumachi, Takatsugu Browse this author →KAKEN DB |
Iizuka, Satoshi Browse this author |
Onimaru, Rikiya Browse this author →KAKEN DB |
Tsuchiya, Kazuhiko Browse this author →KAKEN DB |
Yasuda, Koichi Browse this author →KAKEN DB |
Shirato, Hiroki Browse this author →KAKEN DB |
Fukuda, Satoshi Browse this author →KAKEN DB |
Keywords: | mucositis |
dermatitis |
cisplatin |
radiotherapy |
chemotherapy |
molecular target therapy |
Issue Date: | Aug-2015 |
Publisher: | Taylor & Francis |
Journal Title: | Acta Oto-laryngologica |
Volume: | 135 |
Issue: | 8 |
Start Page: | 853 |
End Page: | 858 |
Publisher DOI: | 10.3109/00016489.2015.1030772 |
PMID: | 25814008 |
Abstract: | Conclusion: Grade ≥ 3 mucositis/stomatitis and inability to feed orally were problematic for patients undergoing cetuximab-based bioradiotherapy (BRT) as well as platinum-based chemoradiotherapy (CRT). Severe mucositis/stomatitis and radiation dermatitis should be addressed carefully in patients undergoing cetuximab-based BRT as well. Objectives: The efficacy of cetuximab-based BRT in locally advanced head and neck squamous cell carcinomas has been established. However, the safety of cetuximab-based BRT in comparison with platinum-based CRT is currently under investigation. Method: This study retrospectively analyzed 14 patients undergoing cetuximab-based BRT and 29 patients undergoing platinum-based CRT to compare the incidence of acute toxicities. In the BRT group, an initial cetuximab loading dose of 400 mg/m2 was delivered 1 week before the start of radiotherapy. Seven weekly infusions of 250 mg/m2 of cetuximab followed during the definitive radiotherapy. In the CRT group, cisplatin was administered at a dose of 40 mg/m2 weekly during the definitive radiotherapy. Results: The BRT group had a higher incidence of Grade ≥ 3 radiation dermatitis than did the CRT group (43% vs 3%, respectively, p < 0.01). The incidence rate of Grade ≥ 3 mucositis/stomatitis was 64.3% and 41.4% in the BRT and CRT group, respectively (p = 0.1484), while the incidence rate of the inability to feed orally was 38.5% and 55.2%, respectively (p = 0.2053). |
Rights: | This is an Accepted Manuscript of an article published by Taylor & Francis in Acta Oto-Laryngologica on 2015, available online: http://www.tandfonline.com/10.3109/00016489.2015.1030772 |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/62577 |
Appears in Collections: | 国際連携研究教育局 : GI-CoRE (Global Institution for Collaborative Research and Education : GI-CoRE) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc) 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|